Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$212.15 USD

212.15
642,643

+1.37 (0.65%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $211.69 -0.46 (-0.22%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology (ALGN) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Align Technology's (ALGN) second-quarter 2023 results are likely to highlight sustained stability across its Clear Aligner business.

Align Technology's (ALGN) New Pacts, Innovation Aid Growth

by Zacks Equity Research

Align Technology's (ALGN) Invisalign comprehensive witnesses strong initial adoption in the market.

Indrajit Bandyopadhyay headshot

5 Stocks to Buy From the Prospering Dental Supplies Industry

by Indrajit Bandyopadhyay

Here we discuss five stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, ALGN, COO, XRAY and PDCO.

Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Align Technology (ALGN) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Here's Why Investors Should Hold Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology's (ALGN) Invisalign portfolio expansion and strategic alliances.

BDX or ALGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BDX vs. ALGN: Which Stock Is the Better Value Option?

Align's (ALGN) Invisalign Sales Grow Globally Amid Margin Woe

by Zacks Equity Research

Align (ALGN) is confident about a largely untapped market opportunity for digital orthodontics and restorative dentistry.

Align Technology (ALGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Align Technology (ALGN) closed at $304.44, marking a -0.76% move from the previous day.

Here's Why You Should Hold on to Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) owing to expanding work-flow options of its leading iTero scanners.

Align Technology (ALGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Align Technology (ALGN) closed at $302, marking a +1.62% move from the previous day.

Compared to Estimates, Align Technology (ALGN) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Align Technology (ALGN) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Is AmerisourceBergen (ABC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how AmerisourceBergen (ABC) and Align Technology (ALGN) have performed compared to their sector so far this year.

Is a Beat Likely for Cardinal Health (CAH) in Q3 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) third-quarter fiscal 2023 results are expected to reflect solid performance in the Pharmaceutical segment. However, inflationary pressure is likely to have continued.

Align Technology (ALGN) Q1 Earnings Beat, Margins Contract

by Zacks Equity Research

Align Technology (ALGN) delivers better-than-expected revenues and earnings in the first quarter of 2023 but suffers significant foreign currency woes.

Align Technology (ALGN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Align Technology (ALGN) delivered earnings and revenue surprises of 7.69% and 3.84%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

MedTech Stocks' Q1 Earnings on Apr 25: BSX, TMO and More

by Urmimala Biswas

MedTech companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, EW and ALGN fare this time.

STERIS (STE) Set to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) fourth-quarter fiscal 2023 results are likely to reflect an impressive performance across the Healthcare and AST segments, with a gradual improvement in the supply chain.

Should You Buy Align Technology (ALGN) Ahead of Earnings?

by Zacks Equity Research

Align Technology (ALGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BioRad Laboratories (BIO) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Bio-Rad Laboratories' (BIO) first-quarter 2023 results are likely to reflect an impressive performance across its Life Science segment, with a gradual reduction in backlogs and an improvement in the supply chain.

The Zacks Analyst Blog Highlights General Electric, Kimberly-Clark, Corning, Raytheon Technologies and Align Technology

by Zacks Equity Research

General Electric, Kimberly-Clark, Corning, Raytheon Technologies and Align Technology are included in this Analyst Blog.

IDEXX Laboratories (IDXX) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

IDEXX Laboratories' (IDXX) first-quarter 2023 results are expected to reflect an impressive performance in the CAG segment despite inflationary impacts.

Nalak Das headshot

5 U.S. Corporate Bigwigs Set to Beat on Q1 Earnings Next Week

by Nalak Das

We have narrowed our search to five U.S. corporate bigwigs that are set to report first-quarter 2023 earnings results next week. These are: GE, KMB, GLW, RTX and ALGN.

Here's How Much You'd Have If You Invested $1000 in Align Technology a Decade Ago

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Quest Diagnostics' (DGX) first-quarter 2023 results are likely to reflect an impressive performance in its non-COVID-19 base business amid inflationary pressure and labor challenges.

Align Technology (ALGN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Align Technology (ALGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.